Stanley Black & Decker Investing $1 Billion in the U.S. to Drive Innovation, Strengthen U.S. Manufacturing Footprint and Expand the Skilled Trades Workforce Essential to Building America’s Infrastructure

NEW BRITAIN, Conn., Aug. 12, 2026 /PRNewswire/ — As U.S. infrastructure investment accelerates, the construction sector faces a critical challenge: deploying cutting-edge tools and technologies to boost productivity while closing a widening skilled trades gap, with nearly half a million new workers needed by 2027. Against this backdrop, Stanley Black & Decker (NYSE: SWK) is investing $1 billion in the U.S. to advance innovation, develop next-generation tools and solutions, and increase access to training opportunities to expand the skilled trades workforce.

“Our U.S. investment strategy has multiple dimensions and goes far beyond expanding manufacturing – it’s about igniting innovation, building world-class capabilities, and redefining the future of work in America,” said Chris Nelson, Stanley Black & Decker’s President and Chief Executive Officer. “By leaning into research and development and investing in the future of our U.S. operations, we are setting the benchmark for next-generation products and solutions. These investments will empower America’s tradespeople to work safer, reach new levels of productivity, and rise to help solve the nation’s toughest challenges. This is how we plan to lead America forward – by building, competing, and innovating.”

Of the $1 billion Stanley Black & Decker plans to invest through 2028, approximately 50% will go to research and development to accelerate the creation of next-generation tools and breakthrough solutions for trades professionals. The other 50% will support capital expenditures and long-term investments to further strengthen its U.S. manufacturing footprint and support new product development. In addition, Stanley Black & Decker has committed to investing $60 million through its DEWALT Grow the Trades initiative through 2030 – of which $27 million has already been deployed – to expand training programs and open new pathways to rewarding careers in the skilled trades.

“By advancing technology, investing in U.S. manufacturing and expanding training to skilled trades Stanley Black & Decker is helping to build a stronger workforce and a more resilient future for communities across the nation,” said Nelson.

Jay Timmons, President and CEO of the National Association of Manufacturers, underscored the far-reaching impact of Stanley Black & Decker’s investment in the United States. “For more than 180 years, Stanley Black & Decker has helped define what it means to make things in America – innovating, investing and creating opportunities for manufacturing workers and the communities they serve. Their commitment to strengthening U.S. manufacturing and empowering America’s manufacturers exemplifies the leadership our nation needs. These investments not only reinforce our industrial foundation – they open doors to new economic opportunities and secure a brighter future for communities across the country. This is the kind of vision that propels our industry forward.”

About Stanley Black & Decker
Founded in 1843 and headquartered in the USA, Stanley Black & Decker (NYSE: SWK) is a worldwide leader in Tools and Outdoor, operating manufacturing facilities globally. The Company’s approximately 41,000 employees produce innovative end-user inspired power tools, hand tools, storage, digital jobsite solutions, outdoor and lifestyle products, and engineered fasteners to support the world’s builders, tradespeople and DIYers. The Company’s world class portfolio of trusted brands includes DEWALT®, CRAFTSMAN®, STANLEY®, BLACK+DECKER®, and Cub Cadet®. To learn more visit: www.stanleyblackanddecker.com or follow Stanley Black & Decker on Facebook, Instagram, LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements

Forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, are made in this press release, including statements concerning Stanley Black & Decker’s investment, innovation and philanthropy initiatives and anticipated benefits from such initiatives. These forward-looking statements are sometimes identified from the use of forward-looking words such as “believe,” “should,” “could,” “potential,” “continue,” “expect,” “project,” “estimate,” “predict,” “anticipate,” “aim,” “intend,” “plan,” “forecast,” “target,” “is likely,” “will,” “can,” “may” or “would” or the negative of these terms or similar expressions elsewhere in this press release. All forward-looking statements are subject to a number of important factors, risks, uncertainties and assumptions that could cause actual results to differ materially from those described in any forward-looking statements. These factors and risks include, but are not limited to, Stanley Black & Decker’s ability to successfully implement its investment strategy, macroeconomic and geopolitical conditions and other financial, operational and legal risks and uncertainties detailed from time to time in the Company’s risk factors and cautionary statements contained in its filings with the Securities and Exchange Commission. These forward-looking statements represent the Company’s expectations as of the date of this press release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Stanley Black & Decker, Inc.

Source link

Indiana manufacturing push and acquisition drive keep focus on

Eli Lilly & Co. shares on the NYSE traded above USD 1,060 on 06/03/2026 as the United States-based pharma group steps up a multibillion-dollar manufacturing expansion in Indiana and signals a more aggressive acquisition strategy for its drug pipeline.

Eli Lilly & Co. shares remain in focus on the New York Stock Exchange as investors digest the latest signals on the United States company’s capital deployment, combining large-scale manufacturing investments in Indiana with an expanded acquisition strategy to bolster its portfolio of innovative medicines. The stock traded around USD 1,064 on 06/03/2026 on the NYSE under the ticker LLY, according to data cited by GuruFocus as of 06/03/2026, keeping the United States blue chip firmly among the largest healthcare names by market capitalization.

The Indianapolis-based group has been pushing ahead with a sizable expansion of its domestic production base. According to an article published by Manufacturing in Focus on 06/2026, Eli Lilly is topping out its Indiana investment by allocating an additional USD 4.5 billion to its manufacturing footprint in the state, building on earlier commitments to facilities including its LEAP Research and Innovation District near Indianapolis. The report highlights that the expansion is intended to support growing demand for the company’s diabetes and obesity treatments and other biologic therapies, while anchoring high-value pharmaceutical manufacturing in the United States.

Parallel to this capital expenditure program, management has also been signaling a more assertive approach to business development. On 06/03/2026, GuruFocus reported that Eli Lilly’s oncology dealmaker Jacob Van Naarden is leading a significant ramp-up in acquisitions, with more than USD 10 billion of deals already announced in 2026 to acquire or partner with smaller biotech innovators. The article notes that across eight transactions this year, the company has committed over USD 10 billion upfront and potentially up to USD 25 billion when including milestone payments, as it targets cutting-edge assets in oncology and other high-growth therapeutic areas.

The same GuruFocus analysis calculates a proprietary GF Value of USD 1,388.64 per share for Eli Lilly as of 06/03/2026 versus a contemporaneous share price of about USD 1,064.15, implying the stock was trading at roughly a 23.4 percent discount to that intrinsic value estimate. While this is not a market consensus, it illustrates how one valuation framework interprets the company’s growth trajectory, pipeline prospects, and balance sheet strength at the current trading level on the NYSE. For German investors accessing the stock via off-exchange platforms, Eli Lilly is also tradeable on venues such as Tradegate in euros, although liquidity and reference pricing remain centered on the US listing.

Interest from institutional investors continues to underpin trading in the United States. According to a MarketBeat filing summary dated 06/03/2026, Westpac Banking Corp increased its position in Eli Lilly by 39.5 percent in the fourth quarter, purchasing 4,030 additional shares and bringing its total holdings to 14,235 shares. The disclosure underscores how large global asset managers are still adding exposure to the group, with the same MarketBeat overview citing a consensus rating of “Moderate Buy” and an average price target of USD 1,227 among covering analysts as of the latest data. These figures provide a snapshot of how the sell side is framing upside and risk for the stock at current levels.

The combination of escalation in US-based manufacturing investment and heightened acquisition activity is central to how the market evaluates Eli Lilly’s growth case. Investors are paying close attention to whether the expanded Indiana production network will effectively support supply for high-demand medicines, and how quickly newly acquired pipeline assets can be integrated and advanced through clinical trials and regulatory review. With the company’s primary listing and regulatory reporting anchored in the United States, updates via NYSE trading data and SEC filings will remain key reference points for both domestic and international shareholders following the stock.

As of: 06/03/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Eli Lilly & Co.
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Indianapolis, United States
• Core markets: United States, Europe, key international pharmaceutical markets
• Key revenue drivers: Diabetes and obesity therapies, immunology and oncology drugs, other specialty pharmaceuticals
• Home exchange/listing venue: New York Stock Exchange (LLY)
• Trading currency: USD

Eli Lilly & Co.: core business model

Eli Lilly focuses on discovering, developing, and commercializing branded prescription medicines, with revenue concentrated in chronic disease areas such as diabetes, obesity, immunology, and oncology that can support long product lifecycles and premium pricing.

Eli Lilly & Co. in peer comparison

In the global large-cap pharmaceutical space, Eli Lilly is often assessed alongside peers such as Novo Nordisk, Pfizer, and Johnson & Johnson, which likewise operate diversified portfolios of patented therapies and vaccines. Novo Nordisk, for example, has also invested heavily in obesity and diabetes medicines and reached a market capitalization above USD 500 billion in early 2026 on the back of demand for GLP-1-based treatments, underlining the scale of the metabolic disease opportunity for sector leaders. Pfizer, by contrast, has been reallocating cash flows from its COVID-19 franchise into pipeline rebuilds and bolt-on acquisitions, while Johnson & Johnson maintains a more diversified business that includes medical devices and consumer health in addition to pharmaceuticals.

Compared with these peers, Eli Lilly’s current strategy of combining substantial US manufacturing commitments in Indiana with an enlarged acquisition budget exceeding USD 10 billion in 2026 places it toward the more aggressive end of the spectrum in terms of reinvesting cash into long-term growth initiatives. Investors monitoring the stock on the NYSE and in European trading are therefore weighing similar questions across the peer group: how quickly new metabolic and oncology products can be scaled, how effectively supply chains can keep pace with demand, and whether the balance between shareholder returns and reinvestment supports sustainable earnings growth.

Sentiment and reactions on Eli Lilly & Co.

The combination of expanded Indiana manufacturing investment and a more active acquisition pipeline has sparked ongoing discussion among market participants on social platforms about how these moves might influence Eli Lilly & Co.’s long-term earnings power and valuation.

YouTubeXTikTokInstagram

Conclusion

Eli Lilly & Co. remains a closely watched United States healthcare stock, with its NYSE-listed shares trading just above USD 1,060 on 06/03/2026 as the group deploys capital into an expanded Indiana manufacturing footprint and a stepped-up acquisition agenda. The latest reports on more than USD 10 billion of 2026 dealmaking and an additional USD 4.5 billion in state-side plant investment highlight the company’s decision to prioritize future capacity and pipeline breadth alongside ongoing shareholder returns.

For investors comparing Eli Lilly & Co. with global pharma peers such as Novo Nordisk, Pfizer, and Johnson & Johnson, the current strategy underscores a distinct emphasis on scaling high-demand metabolic and oncology therapies through both organic infrastructure builds and external innovation sourcing. How effectively these initiatives translate into sustained revenue and earnings growth over the medium term will remain central to how the stock is valued on the New York Stock Exchange and in secondary trading venues worldwide.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.

en | US5324571083 | ELI LILLY & CO. | boerse | 69478848 | bgmi

Source link

Tariffs drive companies to expand manufacturing in U.S., Gerdau says

Gustavo Werneck, chief executive of Gerdau, said the U.S. administration’s tariff policy may be viewed as an unexpected measure, but it also reflects a long-term vision and confidence in the revival of American industry.

According to Werneck, Gerdau does not base its investment decisions on short-term volatility and continues to invest because it believes in the long-term recovery of U.S. manufacturing.

“There has been an additional incentive for Brazilian companies to establish manufacturing operations here in the United States,” Werneck said during the third edition of the Summit Valor Brazil-USA on Wednesday in New York.

The executive, who took part in a panel on trade and investment relations between Brazil and the United States, said the cost of key industrial inputs such as energy and natural gas in the U.S. is unmatched, making it impossible to offset the price gap between the two countries solely through management efficiency.

“In Brazil, we pay around $16 per cubic meter of natural gas. Here, despite all the volatility, we are still paying around $4,” he said.

Gerdau operates 13 of its 29 steel production units in North America, with facilities spread across the United States and Canada.

According to Werneck, the reindustrialization of the U.S. is already visible through customers building new factories in the country.

“We are currently supplying a significant amount of steel to new semiconductor plants being established here,” he added.

Gustavo Werneck — Foto: Vanessa Carvalho/Valor



Source link

Does U.S. manufacturing edge now drive sustained outperforman

As solar demand surges in the U.S., First Solar’s domestic production positions it ahead of import-reliant rivals. This could matter for your portfolio amid policy shifts and energy transitions. ISIN: US3364331070

First Solar Inc. stands out in the solar industry with its focus on thin-film photovoltaic modules manufactured entirely in the United States. You benefit from this as an investor because it shields the company from international trade tensions and aligns directly with domestic energy policies pushing for American-made clean tech. The stock’s performance ties closely to global renewable adoption, but its U.S.-centric model gives it a unique stability in volatile markets.

Updated: 21.04.2026

By Elena Vargas, Senior Energy Markets Editor – Exploring how U.S. policy shapes solar stock opportunities for investors.

Core Business Model and Technology Edge

First Solar specializes in cadmium telluride (CdTe) thin-film solar panels, which differ from the crystalline silicon modules dominating the market. This technology allows for lower production costs and higher efficiency in hot climates, key advantages as solar expands into diverse regions. You see value here because the company’s proprietary process reduces material use and energy in manufacturing, supporting higher margins over time.

The business model emphasizes vertical integration, controlling everything from module production to utility-scale project development. This setup minimizes supply chain risks, especially critical in an industry prone to raw material shortages. For U.S. investors, this means First Solar captures more value domestically without relying on overseas components.

Recent expansions in Ohio and Alabama factories underscore commitment to scaling U.S. capacity. These facilities position the company to meet rising demand from data centers and electrification trends. As a result, you get exposure to growth without the geopolitical baggage of imported panels.

Official source

All current information about First Solar Inc. from the company’s official website.

Visit official website

Key Markets and Growth Drivers

The U.S. solar market leads First Solar’s opportunities, fueled by Inflation Reduction Act incentives for domestic content. You watch this closely because subsidies favor U.S.-made modules, boosting project economics for utilities and developers. Internationally, markets like India and Australia provide diversification, but North America remains the core.

Utility-scale solar dominates the company’s backlog, with multi-gigawatt contracts signaling long-term revenue visibility. Emerging demand from commercial and residential segments adds upside, though execution matters. For investors in the United States, this translates to steady cash flows amid the push for net-zero goals.

Industry tailwinds include falling battery storage costs and grid modernization needs. First Solar pairs well with these, as its modules integrate into hybrid projects. You position yourself for compound growth as renewables hit 50% of U.S. power by decade’s end.

Market mood and reactions

Competitive Position in Solar Landscape

First Solar differentiates through American manufacturing, avoiding tariffs on Chinese imports that plague silicon competitors. This gives it a cost edge in U.S. projects, where domestic content rules apply. You appreciate this resilience as trade policies evolve under various administrations.

Compared to peers like Enphase or Sunrun, First Solar focuses on large-scale modules rather than inverters or rooftops. This specialization yields economies of scale, with factory utilization driving profitability. Globally, its thin-film tech competes on performance in high-temperature areas, opening niche leadership.

Sustainable practices enhance its position, with recycling programs reducing end-of-life waste. Investors value this ESG alignment, especially as funds screen for green credentials. Overall, the company’s moat strengthens with every new U.S. factory online.

Investor Relevance for U.S. and Global English-Speaking Markets

For you as a U.S. investor, First Solar offers pure-play exposure to the world’s largest solar growth story without currency or political risks from Asia. Tax credits and grants flow directly to domestic producers, padding earnings. Across English-speaking markets like the UK, Australia, and Canada, similar renewable mandates create parallel demand.

Your portfolio diversifies through this stock, balancing tech-heavy indexes with energy transition bets. Dividend potential emerges as free cash flow grows, appealing to income seekers. Policy continuity under pro-clean energy governments amplifies upside for North American holders.

English-speaking markets worldwide share regulatory pushes for emissions cuts, favoring established players like First Solar. You track bipartisan U.S. support for solar, which insulates the stock from election cycles. This makes it a core holding for long-term decarbonization themes.

Analyst Views and Coverage

Reputable analysts generally view First Solar positively, citing its manufacturing leadership and policy tailwinds as key strengths. Firms highlight the robust order backlog and margin expansion potential from U.S. operations. Coverage emphasizes execution on capacity ramps as a watch item for sustained performance.

Consensus leans toward buy ratings from major banks, reflecting confidence in solar demand outpacing supply constraints. Price targets suggest upside from current levels, driven by earnings growth forecasts. You consider these alongside your risk tolerance, as sector volatility persists.

Recent notes praise the company’s balance sheet strength, enabling aggressive expansion without dilution. Analysts note competitive advantages in thin-film efficiency for utility projects. Overall assessments position First Solar as a top pick in renewables for U.S.-focused portfolios.

Analyst views and research

Review the stock and make your decision. Here you can access verified analyses, coverage pages, or research references related to the stock.

Risks and Open Questions

Read more

More developments, headlines, and context on the stock can be explored quickly through the linked overview pages.

Policy changes pose the biggest risk, as subsidy reliance could shift with elections or budget cuts. You monitor Washington closely, since IRA extensions remain uncertain. Supply chain issues for tellurium, though mitigated by contracts, warrant attention.

Competition intensifies from low-cost Asian producers if tariffs ease. Technological leaps in perovskites or silicon could challenge thin-film dominance. For your portfolio, diversify to hedge sector downturns tied to interest rates.

Execution risks include factory delays or project cancellations in the backlog. Environmental concerns over cadmium require vigilant compliance. Watch quarterly updates for margin trends and backlog conversion rates.

What to Watch Next for Investors

Upcoming earnings will reveal capacity utilization and guidance updates, critical for stock direction. You focus on U.S. project awards, signaling policy momentum. International expansions provide diversification clues.

Regulatory filings on new factories offer growth visibility. Peer comparisons highlight relative strength. Macro energy prices influence solar economics, so track natural gas trends.

Long-term, battery integration and grid contracts define upside. Position yourself by reviewing positions quarterly against these milestones. This disciplined approach maximizes your returns in renewables.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.

en | US3364331070 | FIRST SOLAR INC. | boerse | 69224500 | bgmi

Source link